Business Context and Reporting Period
This Form 10-Q covers Schering-Plough Corporation for the quarterly and nine-month periods ended September 30, 1995. The filing reflects the completion of a 2-for-1 stock split in June 1995 and the sale of the worldwide contact lens business, which is now reported as a discontinued operation. The company operates primarily in pharmaceutical and health care products, facing competitive pricing pressures in the U.S. and government-mandated cost containment internationally.
Key Financial Metrics
| Metric (in millions) | Q3 1995 | Q3 1994 | 9M 1995 | 9M 1994 |
|---|---|---|---|---|
| Sales | $1,256.8 | $1,095.2 | $3,813.5 | $3,377.1 |
| Income from Continuing Ops | $252.6 | $226.2 | $813.6 | $714.7 |
| Net Income | $252.6 | $224.3 | $647.2 | $718.2 |
| EPS (Continuing Ops) | $0.68 | $0.59 | $2.19 | $1.86 |
| EPS (Total) | $0.68 | $0.59 | $1.74 | $1.87 |
| Operating Cash Flow (9M) | $995.8 (9M 1995) vs $837.9 (9M 1994) | |||
| Cash & Equivalents | $336.7 (Sep 30, 1995) vs $115.6 (Dec 31, 1994) | |||
| Long-Term Debt | $86.3 (Sep 30, 1995) vs $185.8 (Dec 31, 1994) |
Margins (9M 1995 vs 1994): Pre-tax income margin improved to 28.3% from 28.0%. Cost of sales ratio declined slightly to 19.6% from 19.7%. SG&A expenses rose to 38.7% of sales from 38.6%.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 15% in Q3 and 13% for the nine months ended September 30, 1995. Organic growth (excluding currency) was 12% for the quarter and 10% for the nine months.
- Discontinued Operations: The sale of the contact lens business resulted in a one-time loss on disposal of $156.2 million (net of tax) for the nine-month period, significantly impacting total net income compared to continuing operations.
- Share Repurchases: The company repurchased $268.0 million of common shares in the first nine months of 1995, part of a $500 million program authorized in June 1995.
- Product Performance: Domestic prescription pharmaceutical sales grew 27% in Q3, driven by CLARITIN, VANCENASE, and VANCERIL. International sales grew 3% (excluding currency), though INTRON A sales declined in Japan due to government cost-containment.
Guidance, Outlook, and Risks
- Outlook: Management anticipates total R&D expenses to approximate $650 million for the full year 1995. Future operations face uncertainty due to potential U.S. health care reform and international government-mandated price cuts.
- Legal Contingencies:
- THEO-DUR Litigation: A $63.6 million judgment (including $57.5 million punitive damages) was entered in 1994. The company is appealing and has sued its insurance carriers regarding coverage for punitive damages.
- Antitrust Actions: The company is a defendant in over 145 antitrust actions alleging price discrimination and conspiracy. Plaintiffs seek unspecified treble damages. Management believes these claims are without merit.
- Competitive Risks: Generic competition is expected to negatively affect PROVENTIL sales following FDA bioequivalence standards. Managed care groups are increasing pressure for price discounts.
Investor Verification Checklist
- Verify the status of the appeal regarding the $63.6 million THEO-DUR judgment and the outcome of the lawsuit against insurance carriers.
- Monitor the progress of the 145+ antitrust class action lawsuits and potential exposure to treble damages.
- Assess the impact of generic albuterol inhaler market entry on PROVENTIL profitability.
- Review the completion status of the $500 million share repurchase program authorized in June 1995.
- Track international sales performance, specifically INTRON A in Japan, amidst government cost-containment measures.